MENLO PARK, Calif.--(BUSINESS WIRE)--New Enterprise Associates, Inc. (NEA) today announced that the firm has led a Series D investment in San Diego, California-based Novalar Pharmaceuticals, Inc. The funds will be used to support Novalar’s anticipated U.S. launch of NV-101, a first-in-class, local dental anesthetic reversal agent, as well as the development of other innovative dental pharmaceuticals in the company’s pipeline. As a result of the investment, NEA Partner Michael Raab will join Novalar’s Board of Directors.
